Usern_member

Mhammad Ali Sahraian

USERN Advisory Board
Dr. Sahraian graduated from Shiraz University of Medical Sciences (Shiraz-Iran). He undertook board of neurology and fellowship in medical education from Tehran University of Medical sciences. Dr. Sahraian had a training in multiple sclerosis at University hospital Basel (Switzerland). He is currently an associate p

rofessor of neurology and the director of MS research center in Tehran University of Medical Sciences and vice-chancellor for Iranian MS society.

He has served as an investigator on several clinical trials in neurology and has published more than 130 articles in peer-reviewed journals and presented abstracts on MS at international meetings. He has been invited to deliver several lectures on MR evaluations and disability assessment at different meetings on multiple sclerosis. He has published “MRI atlas of lesions in multiple sclerosis” and has been the author of “Multiple Sclerosis” chapter in Encyclopedia of Diagnostic Imaging. He is one of the authors of MRI Training CD-ROM which was translated into four languages. Dr. Sahraian areas of interests are management of multiple sclerosis and neuromyelitis optica. 




Education:



2006 – 2007

Fellowship in “MS”

MS Research Group

Basel University Hospital

Basel - Switzerland




1997 – 2001

Course of Specialty in “Neurology”

Tehran University of Medical Sciences

Tehran – Iran




1991 – 1997

General Medicine (MD)

Shiraz University of Medical Sciences

Shiraz– Iran





Highlighted Educational/Occupational Qualifications:




• 1st Prize, Editting the book “MRI Atlas of MS Lesions”

• 1st Rank, National Neurology Board Exam, 2002

• 1st Rank, National University Entrance Exam, 1991







Professional Society Membership:




2001-Present                Iranian Neurological Association

1997 – Present The Iranian Medical Organization






Work Experience:




Executive Activities

• 2017-present: Chairman in Research Deputy, Tehran University of Medical Sciences

• 2014- present: Member of university MS committee, Tehran university of medical sciences

• 2014-present: Head of MS ward, Sina University Hospital

• 2014-present: Deputy of higher education and training at Department of Neurology, Tehran University of Medical Sciences

• 2013- present: Section editor of  Iranian Journal of Neurology

• 2013-present: Head of MS Research Center, Neuroscience Institute 

• 2012- present: Head of medical ethics committee, Sina University Hospital

• 2011-presnt: Director of National MS committee at Minestery of Health

• 2010-2014: Member of Fellowship and subspecialty development committee at MOH  

• 2010-present: Senior consultant for director of Sina University Hospital

• November 2008: Program director of the 5th National MS Congress, Tehran – Iran 

• 2008-Present: Vice chancellor for Iranian MS Society

• 2008: Member of the Scientific Committee, MS International Federation (MSIF)

• 2007 – 2009: Member of Mortality & Morbidity Committee, Sina University Hospital

• 2007 – Present: Member of the Research Committee, Iranian Center for Brain & Spinal Cord Repair  

• 2007– 2011: Head of Education Development Office, Sina University Hospital

• 2007– Present: Head of MS Clinic & Research Center, Sina University Hospital

• 2007– Present: President of the scientific advisory board, Iranian MS Society

• November 2004: Program director of the 1st National Multiple Sclerosis Congress, Tehran – Iran 

• 2004 – 2006: Member of MS Research Committee, The Iranian Center for Neurological Research

• 2003 – 2005: Director of international relations, Iranian MS Society

• May 2003: Program director of the 10th international congress on Neurology & Electrophysiology, Tehran – Iran 

• 2002 – 2006: Program director of medical student, Department of Neurology, Sina University Hospital

• 2002 – 2006: Consultant neurologist, Tehran Heart Center

• 2002 – Present: Member of the Scientific Committee, Iranian MS Society

• 2002 – 2008: Member of the Research Committee, Department of Neurology, Sina University Hospital




Clinical Activities




2001 – Present

SINA UNIVERSITY HOSPITAL

Neurologist

Tehran – Iran




Editorial Activities

• Member of the editorial board of “Iranian Journal of Neurology” (since 2003)






Teaching Service:




2016 – Present

TEHRAN UNIVERSITY OF MEDICAL SCIENCES

Professor

Tehran – Iran




2008 – Present

TEHRAN UNIVERSITY OF MEDICAL SCIENCES

Associate Professor

Tehran – Iran




2002 – 2008

TEHRAN UNIVERSITY OF MEDICAL SCIENCES

Assistant Professor

Tehran – Iran







Thesis:



1. Sharareh Eskandarieh, Environmental risk factors in Neuromyelitis optica, PhD by Research, 2014-2018 (Advisor)

2. Shokoofe Sadaghiani, determining the relationship between cerebral volums and motor and cognitive function tests in multiple sclerosis, General medicine, completed June 2014 (Advisor) 

3. Mehdi Mohammadi, Association study of four polymorphisms of NPY gene and its receptors Y1 with MS, master, completed Feb 2014 (Cnosultant)

4. Pooria Heydarpour, subnational disease burden of multiple sclerosis in Tehran Iran, General medicin, completed (Advisor)

5. Fatemeh Omrani, Prevalence of demographic findings in patients with early-onset multiple sclerosis referred to MS Association of Iran during the past 10 years, General medicin, completed 2013 (Advisor)

6. Seyed Ali Jzayeri, Evaluation of serum levels of vitamin D and its receptor in patients with MS and neuromyelitis optica syndrom treated with additives, General medicin, completed 2013 (Advisor)

7. Farnaz Najmi Varzaneh, Association of vitamin D receptor polymorphism FokI with a variety of MS in patients referred to the hospital in 1390-91, General medicin, completed 2013 (Advisor)

8. Raziyeh Gorji, The relationship between season of birth and risk of MS in Tehran, General medicin, completed 2013 (consultant) 

9. Mahin Besharati, Effects of corticosteroid therapy in the prevention of  enhancing plaque turns to black hole in patients with MS, Specialty course of “Neurology”, completed 2013 (Advisor)

10. Mahsa Oji, The prevalence of familial MS in patients referred to the MS clinic of Sina hospital in 1391, General medicin, completed in 2012 (Advisor)

11. Fatemeh Khajvand, The relationship between response to corticosteroid treatment in MS patients with serum levels of hs-CRP during relapse, Master, completed in 2011 (Consultant)

12. Zahra Sadat Koleyni, The underlieing pattern in the association of stressful life events and multiple sclerosis, General medicin, completed 2012 (Advisor) 

13. Narges Shahbazi, Determination of the prevalence of different types of headache in MS patients, General medicin, Completed in 2011 (Consultant)

14. Elahe Naraghi, Investigation of relationship between NDUFS8 gene and MS  disease, Master, Completed in July 2011 (Consultant)

15. Somaye Baghizadeh,  The relationship between clinical and demographic findings with MS disease severity, Specialty Course of “Neurology”,Completed in 2010 (Consultant)

16. Mehrzad Roghani, Study on cytokine expression level and nitric oxide concentration in blood of Iranian MS patients, PHD, Completed in Dec 2010 (Consultant)

17. Mohammad Bagherzadeh, Association of inflammatory biomarkers with sleep disorders in hemodialysis, Specialty Course of “Neurology, Completed in 2011 (Consultant)

18. Samira Navardi, Frequency and distribution of magnetic resonance imagings findings, Specialty Course of “Neurology”,Completed in 2010 (Advisor)

19. Soha Mirreza, Check for anemia and fatigue in MS patients referred to the MS clinic of Sina hospital in the second half of 1387, General medicin, completed in 2011 (Advisor)

20. Moones Heydari, Association study of IL7Ra gene polymorphisms in Iranian multiple sclerosis patients, Master, Completed in 2009 (Consultant)

21. Mohammad Mehdi Omidian, effect of interferon-B 1a on interlukin 12 in patients in patients with relapcing remitting MS, General medicin, Completed in 2009 (Advisor)

22. Nooshin Moradi, Prevalence and factors associated with Orofacial protests in MS patients admitted to the MS Society of Iran in 1387, General medicin, Completed in 2008 (Consultant)

23. Mahshid Sadeghi, Evaluation of fatigue and sleep disturbances in patients with multiple sclerosis and its relation to the clinical course of disease in patients admitted to Sina hospital during the years 1386-1387, General medicin, Completed in 2009 (Advisor)

24. Mahboobe Moradi, effect of eight week resistance training on motor function, muscular strength and balance in men with MS, Master, Completed in 2009 (Consultant)

25. Zahra Golzari, Effect of period selected combine training for physical and movement fitness and EDSS in multiple sclerosis patients, General medicin, Completed in Nov 2008  (Consultant)

26. Soode Mohebirasa, The effect of Ginkgo biloba on improving memory impairment and quality of life of MS patients referred to MS clinicof the Sina hospital or Iran MS Society from 1385, Specialty Course of “Neurology”, Completed in 2008 (Consultant)

27. Fereshteh Naderi, Effect of Primidone on Tremors of patients with MS Specialty Course of “Neurology”, (Advisor)

28. Lila Darabi, Cardiac holter monitoring in patients with MS receiving IV methyle prednisolone, Specialty Course of “Neurology”, completed 2010 (Advisor)

29. Aida Aghsaiee, ApoE in Patients with clinically isolated syndrome, General Medicine, completed (Advisor)

30. Maryam Vejdani, Autoimmune disease in MS patients, General Medicine, 2008 (Advisor)

31. Babak Moghimi, Prevalence of APO  E in patients with optic neuritis, General Medicine, 2007 (Consultant) 

32. Saiedeh Khoramnia, Pregnancy outcome in patients with Multiple Sclerosis, General Medicine, 2007 (Consultant) 

33. Maryam Abedini, Evaluation of serum and CSF magnesium in MS patients, Specialty course of “Neurology”, 2007 (Advisor) 

34. Vahid Eslami, Evaluation of glucose tolerance test in non diabetic stroke patients, General Medicine, 2006 (Advisor) 

35. Amin Haghighat, Mortality and Morbidity after carotid endartherctomy in Sina hospital. General Medicine, 2006 (Consultant)

36. Sara Alighanbari, ALS in Iran, Demographic data of 200 cases, General Medicine 2006 (Consultant)

37. Kiafar nilavari, Evaluation of chelamidia pneumonia infection in patients with ischemic stroke, Specialty course of “Neurology”, 2005 (Consultant)  

38. Mehdi Firozi, Evaluation of seizure in stroke patients during hospital course, General Medicine, 2005 (Advisor) 

39. Afsaneh shirani, Evaluation of serum prolactin in patients with multiple sclerosis, General Medicine, 2005 (Consultant) 

40. Mehdi Khoram, Evaluation of subarachnoid hemorrhage in Sina Hospital, General Medicine, 2005 (Consultant) 

41. Reza Kazemizadeh, Neurologic complications of kidney transplant in Sina hospital, General Medicine, 2005 (Advisor) 

42. Farinaz safavi, Complications of antiepileptic drugs in pregnancy, General Medicine, 2005 (Advisor) 

43. Mehdi Nazari, Neurlogical complication of bone marrow transplantation, General Medicine, 2005 (Advisor) 

44. Masoud Rahmat, Comparison of Valporic acid efficacy in familial versus sporadic cases of Juvenile Myoclonic epilepsy, Specialty course of “Neurology”, 2005 (Consultant) 

45. Kamran Mostehaghan, Post-mortem cerebrospinal fluid analysis in ICU admitted patients, Specialty course of “Anesthesialogy”, 2005 (Consultant) 








Books:



English


1. Radue EW, Shraian MA, Bacelor O, Devera A, Haller S. MS In MRI (Learninig and Training CD. Regarde (Switzerland) 2008

2. Sahraian MA, Radue EW. MRI Atlas of MS lesions in Multiple Sclerosis. Springer Publications (Germany), 2008 

3. Sahraian MA. Multiple Sclerosis (Chapter) in Encyclopedia of Diagnostic Imaging. Springer Publications (Germany), 2008 




Farsi

4. Sahraian MA. Muscle diseases (Classification Chapter). Tehran university of Medical Sciences Publications (Germany), 2005 







Articles:




1. Mohajer B, Abbasi N, Pishgar F, Abdolalizadeh A, Ebrahimi H, Razaviyoun T, Mohebbi F, Eskandarieh S, Sahraian MA. HLA-DRB1 polymorphism and susceptibility to multiple sclerosis in the Middle East North Africa region: A systematic review and meta-analysis. J Neuroimmunol. 2018 Aug 15;321:117-124.




2. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. GBD 2016 Healthcare Access and Quality Collaborators. Lancet. 2018 Jun 2;391(10136):2236-2271




3. Rahmanzadeh R, Brück W, Minagar A, Sahraian MA. Multiple sclerosis pathogenesis: missing pieces of an old puzzle. Rev Neurosci. 2018 Jun 8. 




4. Koolaji S, Allahabadi NS, Ahmadi A, Eskandarieh S, Moghadasi AN, Azimi AR, Sahraian MA. Anti-JC virus antibody sera positivity and index value among patients with multiple sclerosis may be correlated with age, sex, and area of residence. J Neurovirol. 2018 May 21.




5. Amini Harandi A, Esfandani A, Pakdaman H, Abbasi M, Sahraian MA. Balo's concentric sclerosis: an update and comprehensive literature review. Rev Neurosci. 2018 May 16.




6. Abdollahpour I, Nedjat S, Mansournia MA, Sahraian MA, Kaufman JS. Estimating the Marginal Causal Effect of Fish Consumption during Adolescence on Multiple Sclerosis: A Population-Based Incident Case-Control Study. Neuroepidemiology. 2018;50(3-4):111-118.




7. Abdollahpour I, Nedjat S, Mansournia MA, Sahraian MA, van der Mei I.



8. Lifestyle factors and multiple sclerosis: A population-based incident case-control study. Mult Scler Relat Disord. 2018 May;22:128-133.




9. Heydarpour P, Manouchehrinia A, Beiki O, Mousavi SE, Abdolalizadeh A, -Lakeh MM, Sahraian MA. Smoking and worsening disability in multiple sclerosis: A meta-analysis. Acta Neurol Scand. 2018 Jul;138(1):62-69.




10. Shahmohammadi S, Sahraian MA, Shahmohammadi A, Doosti R, Zare-Mirzaie A, Naser Moghadasi A. A presentation of ulcerative colitis after rituximab therapy in a patient with multiple sclerosis and literature review. Mult Scler Relat Disord. 2018 May;22:22-26.




11. Rahmanzadeh R, Weber MS, Brück W, Navardi S, Sahraian MA. B cells in multiple sclerosis therapy-A comprehensive review. Acta Neurol Scand. 2018 Jun;137(6):544-556.




12. Eskandarieh S, Nedjat S, Abdollahpour I, Azimi AR, Moghadasi AN, Asgari N, Sahraian MA. Environmental risk factors in neuromyelitis optica spectrum disorder: a case-control study. Acta Neurol Belg. 2018 Jun;118(2):277-287.




13. Roostaei T, Sadaghiani S, Mashhadi R, Falahatian M, Mohamadi E, Javadian N, Nazeri A, Doosti R, Naser Moghadasi A, Owji M, Hashemi Taheri AP, Shakouri Rad A, Azimi A, Voineskos AN, Nazeri A, Sahraian MA. Convergent effects of a functional C3 variant on brain atrophy, demyelination, and cognitive impairment in multiple sclerosis. Mult Scler. 2018 Feb 1:1352458518760715.







14. Baghbanian SM, Asgari N, Sahraian MA, Moghadasi AN. A comparison of pediatric and adult neuromyelitis optica spectrum disorders: A review of clinical manifestation, diagnosis, and treatment. J Neurol Sci. 2018 May 15;388:222-231.




15. Navardi S, Sahraian MA. A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy. Mult Scler Relat Disord. 2018 Apr;21:69-70.




16. Eskandarieh S, Allahabadi NS, Sadeghi M, Sahraian MA. Increasing prevalence of familial recurrence of multiple sclerosis in Iran: a population based study of Tehran registry 1999-2015. BMC Neurol. 2018 Feb 7;18(1):15




17. Salehi F, Abdollahpour I, Nedjat S, Sahraian MA, Memari AH, Rahnama M, Mansournia MA. Uncovering the link between reproductive factors and multiple sclerosis: A case-control study on Iranian females. Mult Scler Relat Disord. 2018 Feb;20:164-168.




18. Rahmanzadeh R, Sahraian MA, Rahmanzade R, Rodriguez M. Demyelination with preferential MAG loss: A complex message from MS paraffin blocks. J Neurol Sci. 2018 Feb 15;385:126-130.




19. Abdollahpour I, Nedjat S, Mansournia MA, Sahraian MA, Asgari N.

Parental ethnicity associated with risk for multiple sclerosis: A population-based incident case-control study in Iran. Mult Scler Relat Disord. 2018 Feb;20:100-103.




20. Pakbaz Z, Sahraian MA, Sabzi S, Mahmoodi M, Pourmand MR. Prevalence of sea, seb, sec, sed, and tsst-1 genes of Staphylococcus aureus in nasal carriage and their association with multiple sclerosis. Germs. 2017 Dec 5;7(4):171-177.




21. Pazhouhandeh M, Sahraian MA, Siadat SD, Fateh A, Vaziri F, Tabrizi F, Ajorloo F, Arshadi AK, Fatemi E, Piri Gavgani S, Mahboudi F, Rahimi Jamnani F. A systems medicine approach reveals disordered immune system and lipid metabolism in multiple sclerosis patients. Clin Exp Immunol. 2018 Apr;192(1):18-32.




22. Sharareh Eskandarieh, Saharnaz Nedjat, Amir Reza Azimi, Abdorreza Naser Moghadasi, Mohammad Ali Sahraian. Neuromyelitis optica spectrum disorders in Iran. Multiple Sclerosis and Related Disorders 18 (2017) 209–212.




23. GBD 2015 Neurological Disorders Collaborator Group. Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Neurol 2017.




24. GBD 2016 Risk Factors Collaborators.  Global, regional, and national comparative risk assessment of 84 behavioral, environmental and occupational, and metabolic risks or clusters of risks, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017.




25. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators.  Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017.




26. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017.




27. GBD 2016 Mortality Collaborators. Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 2017.







28. GBD 2016 SDG Collaborators. Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet 2017.




29. Sharareh ESKANDARIEH, Pouria HEYDARPOUR, Seyedeh-Robab ELHAMI, Mohammad Ali SAHRAIAN. Prevalence and Incidence of Multiple Sclerosis in Tehran, Iran. Iran J Public Health, Vol. 46, No.5, May 2017, pp.699-704 




30. Sharareh Eskandarieh, Saharnaz Nedjat, Ibrahim Abdollahpour, Abdorreza Naser Moghadasi, Amir Reza Azimi, Mohammad Ali Sahraian.

Comparing epidemiology and baseline characteristic of multiple sclerosis and neuromyelitis optica: A case-control study Original Research Article. Multiple Sclerosis and Related Disorders, Volume 12, February 2017, Pages 39-43  




31. Sharareh Eskandarieh, Pouria Heydarpour, Alireza Minagar, Shadi Pourmand, Mohammad Ali Sahraian. Multiple Sclerosis Epidemiology in East Asia, South East Asia and South Asia: A Systematic Review. Neuroepidemiology 2016; 46:209–221.




32. Sahraian MA, Owji M, Naser Moghadasi A. Concomitant multiple sclerosis and another autoimmune disease: Does the clinical course change? Clinical Neurology and Neurosurgery. Nov 2016. 150. 92-95.




33. Naghdi S, Ansari NN, Ghorbani-rad S, Senobari M, Sahraian MA. Intra-rater reliability of the Modified Tardieu Scale in patients with multiple sclerosis . Neurological Sciences. Sep 2016. 1-7




34. Nasr Z, Majed M, Rostami A, Sahraian MA, Minagar A, Amini, A, McGee JC, Etemadifar M.  Prevalence of multiple sclerosis in Iranian emigrants: review of the evidence. Neurological Sciences. Jun 2016. 1-5.




35. Zare-Shahabadi A, Langroodi HG, Azimi AR, Sahraian MA, Harirchian MH, Baghbanian SM. Neuromyelitis optica and pregnancy. Acta Neurologica Belgica. Jun 2016. 1-8.




36. Kichi Z.A, Khani-Habibabadi F,Sahraian M, Dosti R,Behmanesh M. Association of two polymorphisms in MSH2 and XRCC1 genes with multiple sclerosis in Iranian population. Physiology and Pharmacology. Jun 2016. 20. 2. 83-89.




37. Ghajarzadeh M, Azizi S, Moghadasi AN, Sahraian MA, Azimi A, Mohammadifar M, Bajgiran AM. Validity and reliability of the persian version of the PERception de la scle’rose en plaques et de ses pousse’es questionnaire evaluating multiple sclerosis-related quality of life. International Journal of Preventive Medicine. Jan 2016. 25.




38. Hassanzadeh G, Quchani SH, Sahraian MA, Abolhassani F, Gilani MAS, Tarzjani MD, Atoof F. Leukocyte Gene Expression and Plasma Concentration in Multiple Sclerosis: Alteration of Transforming Growth Factor-beta s, Claudin-11, and Matrix Metalloproteinase-2. CELLULAR AND MOLECULAR NEUROBIOLOGY. Aug 2016. 36. 6. 865-872.




39. Salehi Z, Doosti R, Beheshti M, Janzamin E, Sahraian MA, Izad M. Differential Frequency of CD8+T cell Subsets in Multiple Sclerosis Patients with Various Clinical Patterns. PLOS ONE. Lul 2016. 11. 7.




40. Honarvar NM, Harirchian MH, Abdolahi M, Abedi E, Bitarafan S, Koohdani F, Siassi F, Sahraian MA, Chahardoli R, Zareei M, Salehi E, Geranmehr M, Saboor-Yaraghi AA. Retinyl Palmitate Supplementation Modulates T-bet and Interferon Gamma Gene Expression in Multiple Sclerosis Patients. JOURNAL OF MOLECULAR NEUROSCIENCE. Jul 2016. 59. 3. 360-365.




41. Jahromi SR ,Sahraian MA , Togha M, Sedighi B, Shayegannejad V, Nickseresht A , Nafissi S, Mohebbi N, Majdinasab N, Foroughipour M, Etemadifar M , Moghadam NB, Ayramlou H, Ashtari F, Alaie S. Iranian consensus on use of vitamin D in patients with multiple sclerosis. BMC NEUROLOGY. May 2016. 16.




42. Nejati A, Shoja Z, Shahmahmoodi S, Tafakhori A, Mollaei-Kandelous Y, Rezaei F, Hamid KM, Mirshafiey A, Doosti R, Sahraian MA, Mahmoudi M, Shokri F, Emery V, Marashi SM. EBV and vitamin D status in relapsing-remitting multiple sclerosis patients with a unique cytokine signature. Med Microbiol Immunol. Apr 2016. 205. 2. 143-154. 




43. Roostaei T ,Sadaghiani S, Park, MTM, Mashhadi R, Nazeri A, Noshad S, Salehi MJ, Naghibzadeh M, Moghadasi AN, Owji M , Doosti R, Taheri APH, Rad AS, Azimi A, Chakravarty MM, Voineskos AN, Nazeri A, Sahraian MA. Channelopathy-related SCN10A gene variants predict cerebellar dysfunction in multiple sclerosis. NEUROLOGY. Feb 2016. 86. 5. 410-417.




44. Bitarafan S, Saboor-Yaraghi A, Sahraian MA, Soltani D, Nafissi S, Togha M, Moghadam NB, Roostaei T, Honarvar NM, Harirchian MH. Effect of Vitamin A Supplementation on Fatigue and Depression in Multiple Sclerosis Patients: A Double-blind Placebo-controlled Clinical Trial. IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY. Feb 2016. 15. 1. 13-19.




45. Hamid KM, Nejati A,  Shoja Z, Mollaei-Kandelousd Y ,Doosti R, Mirshafiey A, Tafakhori A, Sahraian MA, Marashi SM. Quantitative Evaluation of BAFF, HMGB1, TLR 4 and TLR 7 Expression in Patients with Relapsing Remitting Multiple Sclerosis. IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY. Feb 2016. 15. 1. 75-81.




46. Moghadasi AN, Pourmand S, Sharifian M , Minagar A, Sahraian MA. Behavioral Neurology of Multiple Sclerosis and Autoimmune Encephalopathies. NEUROLOGIC CLINICS. Feb 2016. 34. 1. 17.




47. Alroughani R, Akhtar S , Ahmed SF, Khoury SJ, Al-Hashel JY, Sahraian MA, Al Jumah M, Zeineddine M, Farhat S, Doumiati H, Yamout BI. JC virus seroprevalence and seroconversion in multiple sclerosis cohort: A Middle-Eastern study. JOURNAL OF THE NEUROLOGICAL SCIENCES. Jan 2016. 360. 61-65.




48. Emamgholipour S, Hossein-Nezhad A, Sahraian MA, Askarisadr F, Ansari M. Evidence for possible role of melatonin in reducing oxidative stress in multiple sclerosis through its effect on SIRT1 and antioxidant enzymes. LIFE SCIENCES. Jan 2016. 145. 34-41.







49. Eskandarieh S, Heydarpour P, Minagar A, Pourmand S, Sahraian MA. Multiple Sclerosis Epidemiology in East Asia, South East Asia and South Asia: A Systematic Review. NEUROEPIDEMIOLOGY. 2016. 46. 3. 209-221.


50. Roostaei T, Sahraian MA, Hajeaghaee S, Gholipour T, Togha M , Siroos B , Mansouri S , Mohammadshirazi, Z, Alasti, MA, Harirchian, MH. Impact of Melatonin on Motor, Cognitive and Neuroimaging Indices in Patients with Multiple Sclerosis. IRANIAN JOURNAL OF ALLERGY ASTHMA AND IMMUNOLOGY. Dec 2015. 14. 6. 589-595







51. GBD 2013 Risk Factors Collaborators,. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. DEC 5 2015. 10. 6736(15)00128-2.




52. Zare-Shahabadi A, Rashidian A, Sahraian MA, Rezaei N. Potential role of immunoglobulin replacement therapy on MRI measures in multiple sclerosis: a systematic review.Expert Rev Clin Immunol. 2015 Oct 21:1-5. 


53. GBD 2013 DALYs and HALE Collaborators, Murray CJ,. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. Lancet. 2015 Aug 27. pii: S0140-6736(15)61340-X. 




54. Bitarafan S, Saboor-Yaraghi A, Sahraian MA, Nafissi S, Togha M, Beladi Moghadam N, Roostaei T, Siassi F, Eshraghian MR, Ghanaati H, Jafarirad S, Rafiei B, Harirchian MH. Impact of Vitamin A Supplementation on Disease Progression in Patients with Multiple Sclerosis. Arch Iran Med. 2015 Jul;18(7):435-40. doi: 0151807/AIM.008.







55. Moradi M, Sahraian MA, Aghsaie A, Kordi MR, Meysamie A, Abolhasani M, Sobhani V. Effects of Eight-week Resistance Training Program in Men With Multiple Sclerosis. Asian J Sports Med. 2015 Jun;6(2):e22838. doi: 10.5812/asjsm.6(2)2015.22838. 







56. Dehghani R, Yunesian M, Sahraian MA, Gilasi HR, Kazemi Moghaddam V. The Evaluation of Multiple Sclerosis Dispersal in Iran and Its Association with Urbanization, Life Style and Industry. Iran J Public Health. 2015 Jun;44(6):830-8.







57. Heydarpour P, Khoshkish S, Abtahi S, Moradi-Lakeh M, Sahraian MA. Multiple Sclerosis Epidemiology in Middle East and North Africa: A Systematic Review and Meta-Analysis. Neuroepidemiology. 2015;44(4):232-44. doi: 10.1159/000431042.




58. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Aug 22;386(9995):743-800. doi: 10.1016/S0140-6736(15)60692-4. Review.




59. Sahraian MA, Moghadasi AN, Owji M, Naghshineh H, Minagar A. Neuromyelitis optica with linear enhancement of corpus callosum in brain magnetic resonance imaging with contrast: a case report. J Med Case Rep. 2015 Jun 10;9:137. doi: 10.1186/s13256-015-0613-9.




60. Saboor-Yaraghi AA, Harirchian MH, Mohammadzadeh Honarvar N, Bitarafan S, Abdolahi M, Siassi F, Salehi E, Sahraian MA, Eshraghian MR, Roostaei T, Koohdani F. The Effect of Vitamin A Supplementation on FoxP3 and TGF-β Gene Expression in Avonex-Treated Multiple Sclerosis Patients. J Mol Neurosci. 2015 Jul;56(3):608-12. doi: 10.1007/s12031-015-0549-y. 




61. Yamout B, Alroughani R, Al-Jumah M, Goueider R, Dahdaleh M, Inshasi J, Hashem S, Alsharoqi I, Sahraian M, Khoury S, Alkawi Z, Koussa S, Zakaria M, Al Khaburi J, Alsaadi T, Bohlega S. Consensus recommendations for the diagnosis and treatment of multiple sclerosis: the Middle East North Africa Committee for Treatment and Research In Multiple Sclerosis (MENACTRIMS). Curr Med Res Opin. 2015;31(7):1349-61. doi: 10.1185/03007995.2015.1047750. 







62. Eskandari G, Ghajarzadeh M, Yekaninejad MS, Sahraian MA, Gorji R, Rajaei F, Norouzi-Javidan A, Faridar A, Azimi A. Comparison of serum vitamin D level in multiple sclerosis patients, their siblings, and healthy controls.  Iran J Neurol. 2015 Apr 4;14(2):81-5.




63. Karabudak R, Dahdaleh M, Aljumah M, Alroughani R, Alsharoqi IA, AlTahan AM, Bohlega SA, Daif A, Deleu D, Amous A, Inshasi JS, Rieckmann P, Sahraian MA, Yamout BI. Functional clinical outcomes in multiple sclerosis: Current status and future prospects. Mult Scler Relat Disord. 2015 May;4(3):192-201. doi: 10.1016/j.msard.2015.03.004. Review.







64. Rezazadeh M, Gharesouran J, Movafagh A, Taheri M, Darvish H, Emamalizadeh B, Shahmohammadibeni N, Khorram Khorshid HR, Behmanesh M, Sahraian MA, Ohadi M. Dominant and Protective Role of the CYTH4 Primate-Specific GTTT-Repeat Longer Alleles Against Neurodegeneration. J Mol Neurosci. 2015 Jul;56(3):593-6. doi: 10.1007/s12031-015-0542-5. 




65. Bahadori Z, Behmanesh M, Sahraian MA. Two functional promoter polymorphisms of neuregulin 1 gene are associated with progressive forms of multiple sclerosis. J Neurol Sci. 2015 Apr 15;351(1-2):154-9. doi: 10.1016/j.jns.2015.03.009. 




66. Gargari BN, Behmanesh M, Sahraian MA. Effect of Vitamin D treatment on Interleukin-2 and Interleukin-4 Genes Expression in Multiple Sclerosis. PHYSIOLOGY AND PHARMACOLOGY. Mar 2015. 19. 1. 14-21




67. Farsani ZS, Behmanesh M, Sahraian MA. Interleukin-10 but not transforming growth factor-β1 gene expression is up-regulated by vitamin D treatment in multiple sclerosis patients. J Neurol Sci. 2015 Mar 15;350(1-2):18-23. doi: 10.1016/j.jns.2015.01.030. 




68. Eshaghi A, Riyahi-Alam S, Saeedi R, Roostaei T, Nazeri A, Aghsaei A, Doosti R, Ganjgahi H, Bodini B, Shakourirad A, Pakravan M, Ghana'ati H, Firouznia K, Zarei M, Azimi AR, Sahraian MA. Classification algorithms with multi-modal data fusion could accurately distinguish neuromyelitis optica from multiple sclerosis. Neuroimage Clin. 2015 Jan 9;7:306-14. doi: 10.1016/j.nicl.2015.01.001. eCollection 2015.




69. Weier K, Banwell B, Cerasa A, Collins DL, Dogonowski AM, Lassmann H, Quattrone A, Sahraian MA, Siebner HR, Sprenger T. The role of the cerebellum in multiple sclerosis. Cerebellum. 2015 Jun;14(3):364-74. doi: 10.1007/s12311-014-0634-8.




70. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015 Jan 10;385(9963):117-71. doi: 10.1016/S0140-6736(14)61682-2. 




71. Nikfallah A, Rezaali S, Mohammadi N, Abrishamkar M, Rezaei E, Sahraian MA , Pakpour AH, Yekaninejad, MS. Translation, Cultural Adaptation and Validation of the Qualiveen-30 Questionnaire in Persian for Patients with Spinal Cord Injury and Multiple Sclerosis. LUTS-LOWER URINARY TRACT SYMPTOMS. Jan 2015. 7. 1. 42-49




72. Weier K, Eshaghi A, Magon S, Andelova M, Radue EW, Kappos L, Azimi AR, Sahraian MA, Sprenger T. The role of cerebellar abnormalities in neuromyelitis optica--a comparison with multiple sclerosis and healthy controls. Mult Scler. 2015 May;21(6):757-66. doi: 10.1177/1352458514554051. 




73. Sarraf P, Azizi S, Moghaddasi AN, Sahraian MA, Tafakhori A, Ghajarzadeh M. Relationship between Sleep Quality and Quality of Life in Patients with Multiple Sclerosis. Int J Prev Med. 2014 Dec;5(12):1582-6.




74. Najmi Varzaneh F, Najmi Varzaneh F, Azimi AR, Rezaei N, Sahraian MA. Efficacy of combination therapy with erythropoietin and methylprednisolone in clinical recovery of severe relapse in multiple sclerosis. Acta Neurol Belg. 2014 Dec;114(4):273-8. doi: 10.1007/s13760-014-0286-y. 




75. Ghajarzadeh M, Owji M, Sahraian MA, Naser Moghadasi A, Azimi A. Emotional Intelligence (EI) of Patients with Multiple Sclerosis (MS). Iran J Public Health. 2014 Nov;43(11):1550-6.




76. Fakharzadeh S, Sahraian MA, Hafizi M, Kalanaky S, Masoumi Z, Mahdavi M, Kamalian N, Minagar A, Nazaran MH. The therapeutic effects of MSc1 nanocomplex, synthesized by nanochelating technology, on experimental autoimmune encephalomyelitic C57/BL6 mice. Int J Nanomedicine. 2014 Aug 11;9:3841-53. doi: 10.2147/IJN.S64630. eCollection 2014.







77. Roostaei T, Nazeri A, Sahraian MA, Minagar A. The human cerebellum: a review of physiologic neuroanatomy. Neurol Clin. 2014 Nov;32(4):859-69. doi: 10.1016/j.ncl.2014.07.013. Review.




78. Al Tahan AM, Alsharoqi I, Bohlega SA, Dahdaleh M, Daif A, Deleu D, Esmat K, Giampaolo D, Freedman MS, Gwilt M, Hosny H, Inshasi JS, Aljumah M, Khalifa A, Pakdaman H, Szólics M, Yamout BI, Sahraian MA, Zakaria MF. Characteristics of multiple sclerosis in the Middle East with special reference to the applicability of international guidelines to the region. Int J Neurosci. 2014 Sep;124(9):635-41. doi: 10.3109/00207454.2013.865620. Review.










79. Naghshineh H, Shahin D, Sahraian MA, Minagar A. Co-existence of neurofibromatosis type 2 and multiple sclerosis: A case report. Mult Scler Relat Disord. 2014 May;3(3):384-6. doi: 10.1016/j.msard.2013.08.008. 




80. Murray CJ, Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014 Sep 13;384(9947):1005-70. doi: 10.1016/S0140-6736(14)60844-8. 







81. Mokhber N, Azarpazhooh A, Orouji E, Rao SM, Khorram B, Sahraian MA, Foroghipoor M, Gharavi MM, Kakhi S, Nikkhah K, Azarpazhooh MR. Cognitive dysfunction in patients with multiple sclerosis treated with different types of interferon beta: a randomized clinical trial. J Neurol Sci. 2014 Jul 15;342(1-2):16-20. doi: 10.1016/j.jns.2014.01.038. 




82. Khalili M, Azimi A, Izadi V, Eghtesadi S, Mirshafiey A, Sahraian MA, Motevalian A, Norouzi A, Sanoobar M, Eskandari G, Farhoudi M, Amani F. Does lipoic acid consumption affect the cytokine profile in multiple sclerosis patients: a double-blind, placebo-controlled, randomized clinical trial. Neuroimmunomodulation. 2014;21(6):291-6. doi: 10.1159/000356145. 







83. Saei M, Holakouie-Naieni K, Mostafavi E, Sahraian MA, Mahmoodi M, Mansournia MA, Hosseini A. Spatial Analysis of Multiple Sclerosis Disease in Tehran Metropolitan Zone, Iran, 2001-2012. Iran J Public Health. 2014 May;43(5):621-9.










84. Askari F, Ghajarzadeh M, Mohammadifar M, Azimi A, Sahraian MA, Owji M. Anxiety in patients with multiple sclerosis: association with disability, depression, disease type and sex. Acta Med Iran. 2014;52(12):889-92.




85. Heydarpour P, Amini H, Khoshkish S, Seidkhani H, Sahraian MA, Yunesian M. Potential impact of air pollution on multiple sclerosis in Tehran, Iran. Neuroepidemiology. 2014;43(3-4):233-8. doi: 10.1159/000368553. 




86. Jalilian R, Ghajarzadeh M, Fateh R, Togha M, Sahraian MA, Azimi A. Comparison of sleep quality in women with migraine moreover, multiple sclerosis. Acta Med Iran. 2014;52(9):690-3.




87. Etemadifar M, Izadi S, Nikseresht A, Sharifian M, Sahraian MA, Nasr Z. Estimated prevalence and incidence of multiple sclerosis in Iran. Eur Neurol. 2014;72(5-6):370-4. doi: 10.1159/000365846.







88. Ghajarzadeh M, Jalilian R, Mohammadifar M, Sahraian MA, Azimi A. Sexual function in women with multiple sclerosis. Acta Med Iran. 2014;52(4):315-8.







89. Bitarafan S, Harirchian MH, Nafissi S, Sahraian MA, Togha M, Siassi F, Saedisomeolia A, Alipour E, Mohammadpour N, Chamary M, Honarvar NM, Saboor-Yaraghi AA. Dietary intake of nutrients and its correlation with fatigue in multiple sclerosis patients. Iran J Neurol. 2014;13(1):28-32.




90. Harirchian MH, Sahraian MA, Hosseinkhani A, Amirzargar N. Level of attitude toward complementary and alternative medicine among Iranian patients with multiple sclerosis. Iran J Neurol. 2014;13(1):13-8.




91. Harandi AA, Harandi AA, Pakdaman H, Sahraian MA. Vitamin D and multiple sclerosis. Iran J Neurol. 2014;13(1):1-6. Review.




92. Kassebaum NJ, Global, regional, and national levels and causes of maternal mortality during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2014 Sep 13;384(9947):980-1004. doi: 10.1016/S0140-6736(14)60696-6. 







93. Heydarpour P, Mohammad K, Yekaninejad MS, Elhami SR, Khoshkish S, Sahraian MA. Multiple sclerosis in Tehran, Iran: a joinpoint trend analysis. Mult Scler. 2014 Apr;20(4):512. doi: 10.1177/1352458513494496. 




94. Jahromi SR, Sahraian MA, Ashtari F, Ayromlou H, Etemadifar M, Ghaffarpour M, Mohammadianinejad E, Nafissi S, Nickseresht A, Shaygannejad V, Togha M, Torabi HR, Ziaie S. Islamic fasting and multiple sclerosis. BMC Neurol. 2014 Mar 22;14:56. doi: 10.1186/1471-2377-14-56. Review.




95. Izadi S, Nikseresht A, Sharifian M, Sahraian MA, Hamidian Jahromi A, Aghighi M, Heidary A. Significant increase in the prevalence of multiple sclerosis in iran in 2011.  Iran J Med Sci. 2014 Mar;39(2):152-3. No abstract available. 







96. Alroughani RA, Aref HM, Bohlega SA, Dahdaleh MP, Feki I, Al Jumah MA, Al-Kawi MZ, Koussa SF, Sahraian MA, Alsharoqi IA, Yamout BI. Natalizumab treatment for multiple sclerosis: Middle East and North Africa regional recommendations for patient selection and monitoring. BMC Neurol. 2014 Feb 12;14:27. doi: 10.1186/1471-2377-14-27. Review.




97. Javadian A, Salehi E, Bidad K, Sahraian MA, Izad M. Effect of estrogen on Th1, Th2 and Th17 cytokines production by proteolipid protein and PHA activated peripheral blood mononuclear cells isolated from multiple sclerosis patients. Arch Med Res. 2014 Feb;45(2):177-82. doi: 10.1016/j.arcmed.2014.01.002. 




98. Balood M, Mesbah-Namin SA, Sanati MH, Zahednasab H, Sahraian MA, Ataei M. Inhibitor IκBα promoter functional polymorphisms in patients with multiple sclerosis. Mol Biol Rep. 2014 Feb;41(2):613-6. doi: 10.1007/s11033-013-2898-3. 







99. Eshaghi A, Bodini B, Ridgway GR, García-Lorenzo D, Tozer DJ, Sahraian MA, Thompson AJ, Ciccarelli O. Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis. Neuroimage. 2014 Feb 1;86:257-64. doi: 10.1016/j.neuroimage.2013.09.059. 




100. Nazeri A, Heydarpour P, Sadaghiani S, Sahraian MA, Burkly LC, Bar-Or A. A further TWEAK to multiple sclerosis pathophysiology. Mol Neurobiol. 2014 Feb;49(1):78-87. doi: 10.1007/s12035-013-8490-y..







101. Yousefzadeh-Fard Y, Gharedaghi MH, Esmaeili S, Pourbakhtyaran E, Sadaghiani MS, Ghorbani A, Sahraian MA. Stroke modifies drug consumption in opium addicts: role of the insula. Basic Clin Neurosci. 2013 Fall;4(4):307-14.




102. Ghajarzadeh M, Jalilian R, Eskandari G, Sahraian MA, Azimi A, Mohammadifar M. Fatigue in multiple sclerosis: relationship with disease duration, physical disability, disease pattern, age and sex. Acta Neurol Belg. 2013 Dec;113(4):411-4. doi: 10.1007/s13760-013-0198-2. 




103. Aljumah M, Alroughani R, Alsharoqi I, Bohlega SA, Dahdaleh M, Deleu D, Esmat K, Khalifa A, Sahraian MA, Szólics M, Altahan A, Yamout BI, Rieckmann P, Daif A. Future of management of multiple sclerosis in the middle East: a consensus view from specialists in ten countries. Mult Scler Int. 2013;2013:952321. doi: 10.1155/2013/952321. 




104. Sahraian MA, Moghadasi AN, Owji M, Maboudi M, Kosari F, McGee JC, Minagar A. Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-β-1b: a case report. J Med Case Rep. 2013 Dec 13;7:270. doi: 10.1186/1752-1947-7-270.




105. Rezaali S, Khalilnezhad A, Naser Moghadasi A, Chaibakhsh S, Sahraian MA. Epidemiology of multiple sclerosis in Qom: Demographic study in Iran. Iran J Neurol. 2013;12(4):136-43.




106. Baghizadeh S, Sahraian MA, Beladimoghadam N. Clinical and demographic factors affecting disease severity in patients with multiple sclerosis. Iran J Neurol. 2013;12(1):1-8.




107. Mohammadzadeh Honarvar N, Harirchian MH, Koohdani F, Siassi F, Abdolahi M, Bitarafan S, Salehi E, Sahraian MA, Eshraghian MR, Saboor-Yarghi AA. The effect of vitamin A supplementation on retinoic acid-related orphan receptor γt (RORγt) and interleukin-17 (IL-17) gene expression in Avonex-treated multiple sclerotic patients. J Mol Neurosci. 2013 Nov;51(3):749-53. doi: 10.1007/s12031-013-0058-9.




108. Emamgholipour S, Eshaghi SM, Hossein-nezhad A, Mirzaei K, Maghbooli Z, Sahraian MA. Adipocytokine profile, cytokine levels and foxp3 expression in multiple sclerosis: a possible link to susceptibility and clinical course of disease. PLoS One. 2013 Oct 3;8(10):e76555. doi: 10.1371/journal.pone.0076555. eCollection 2013. Erratum in: PLoS One. 2013;8(11). doi:10.1371/annotation/6de84c11-73f5-4ee4-aec7-ca83072401a4. PLoS One. 2014;9(1). doi:10.1371/annotation/8fc7e49e-2790-4cfa-900c-2a1e319d61b8. 




109. Sahraian MA, Jafarian S, Sheikhbahaei S, Safavi F. Respiratory tract rather than cutaneous atopic allergy inversely associate with multiple sclerosis: a case-control study. Clin Neurol Neurosurg. 2013 Oct;115(10):2099-102. doi: 10.1016/j.clineuro.2013.07.028. 




110. Bitarafan S, Harirchian MH, Sahraian MA, Keramatipour M, Beladi Moghadam N, Togha M, Nafissi S, Siassi F, Eshraghian MR, Mohammadzadeh Honarvar N, Ansar H, Talebi S, Saboor-Yarghi AA. Impact of vitamin A supplementation on RAR gene expression in multiple sclerosis patients. J Mol Neurosci. 2013 Oct;51(2):478-84. doi: 10.1007/s12031-013-0090-9. 







111. Rezaee AR, Azadi A, Houshmand M, Mahmoodi F, Purpak Z, Safaei S, Karimi P, Ghabaee M, Sahraian MA. Mitochondrial and nuclear genes as the cause of complex I deficiency.Genet Mol Res. 2013 Sep 12;12(3):3551-4. doi: 10.4238/2013.September.12.1.




112. Hossein-Nezhad A, Varzaneh FN, Mirzaei K, Emamgholipour S, Varzaneh FN, Sahraian MA. A polymorphism in the resistin gene promoter and the risk of multiple sclerosis. Minerva Med. 2013 Aug;104(4):431-8.




113. Mohammadi K, Rahnama P, Mohseni SM, Sahraian MA, Montazeri A. Determinants of sexual dysfunction in women with multiple sclerosis. BMC Neurol. 2013 Jul 12;13:83. doi: 10.1186/1471-2377-13-83.




114. Honarvar NM, Harrirchian MH, Koohdani F, Siassi F, Jafari Rad S, Abdolahi M, Bitarafan S, Salehi E, Sahraian MA, Eshraghian MR, Saboor-Yarghi AA. In vitro effect of human serum and fetal calf serum on CD4+ T cells proliferation in response to myelin oligodendrocyte glycoprotein (MOG) in correlation with RBP/TTR ratio in multiple sclerotic patients. J Mol Neurosci. 2013 Jul;50(3):571-6. doi: 10.1007/s12031-013-9999-2.




115. Zahednasab H, Mesbah-Namin SA, Sahraian MA, Balood M, Doosti R. Relationship between NF-κB1 -94 ins/del ATTG polymorphism and susceptibility of multiple sclerosis in Iranian MS patients. Neurosci Lett. 2013 Jun 17;545:46-9. doi: 10.1016/j.neulet.2013.04.014. 




116. Nikfar S, Kebriaeezadeh A, Dinarvand R, Abdollahi M, Sahraian MA, Henry D, Akbari Sari A. Cost-effectiveness of different interferon beta products for relapsing-remitting and secondary progressive multiple sclerosis: Decision analysis based on long-term clinical data and switchable treatments. Daru. 2013 Jun 22;21(1):50. doi: 10.1186/2008-2231-21-50.




117. Parviz M, Sahraian MA, Rezaeizadeh H. Historical Issues of Optic neuritis and Sensory Disorder in Persian Traditional Medicine. Iran J Public Health. 2013 Jun 1;42(6):644-5. eCollection 2013. 




118. Karimi P, Modarresi SZ, Sahraian MA, Shokouhi Shoormasti R, Mahlooji M, Kazemnejad A, Pourpak Z. The relation of multiple sclerosis with allergy and atopy: a case control study. Iran J Allergy Asthma Immunol. 2013 May 15;12(2):182-9.




119. Mohyeddin Bonab M, Mohajeri M, Sahraian MA, Yazdanifar M, Aghsaie A, Farazmand A, Nikbin B. Evaluation of cytokines in multiple sclerosis patients treated with mesenchymal stem cells. Arch Med Res. 2013 May;44(4):266-72. doi: 10.1016/j.arcmed.2013.03.007. 







120. Sahraian MA, Radue EW, Minagar A. Neuromyelitis optica: clinical manifestations and neuroimaging features. Neurol Clin. 2013 Feb;31(1):139-52. doi: 10.1016/j.ncl.2012.09.010. Review.




121. Maghzi AH, Sahraian MA, Shaygannejad V, Minagar A. Is the Iranian revolution to blame for the increasing incidence of multiple sclerosis in Iran? Neuroepidemiology. 2012;40(1):68-9. doi: 10.1159/000341848. 







122. Khalili M, Eghtesadi S, Mirshafiey A, Eskandari G, Sanoobar M, Sahraian MA, Motevalian A, Norouzi A, Moftakhar S, Azimi A. Effect of lipoic acid consumption on oxidative stress among multiple sclerosis patients: a randomized controlled clinical trial. Nutr Neurosci. 2014 Jan;17(1):16-20. doi: 10.1179/1476830513Y.0000000060. 







123. Togha M, Sharifpour A, Ashraf H, Moghadam M, Sahraian MA. Electrocardiographic abnormalities in acute cerebrovascular events in patients with/without cardiovascular disease. Ann Indian Acad Neurol. 2013 Jan;16(1):66-71. doi: 10.4103/0972-2327.107710.







124. Minagar A, Barnett MH, Benedict RH, Pelletier D, Pirko I, Sahraian MA, Frohman E, Zivadinov R. The thalamus and multiple sclerosis: modern views on pathologic, imaging, and clinical aspects. Neurology. 2013 Jan 8;80(2):210-9. doi: 10.1212/WNL.0b013e31827b910b. Review.

125. Faridar A, Eskandari G, Sahraian MA, Minagar A, Azimi A. Vitamin D and multiple sclerosis: a critical review and recommendations on treatment.Acta Neurol Belg. 2012 Dec;112(4):327-33. doi: 10.1007/s13760-012-0108-z.




126. Sahraian MA, Yadegari S, Azarpajouh R, Forughipour M. Avascular necrosis of the femoral head in multiple sclerosis: report of five patients.Neurol Sci. 2012 Dec;33(6):1443-6. doi: 10.1007/s10072-011-0914-8. 




127. Bonab MM, Sahraian MA, Aghsaie A, Karvigh SA, Hosseinian SM, Nikbin B, Lotfi J, Khorramnia S, Motamed MR, Togha M, Harirchian MH, Moghadam NB, Alikhani K, Yadegari S, Jafarian S, Gheini MR. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study.Curr Stem Cell Res Ther. 2012 Nov;7(6):407-14.




128. Nick ST, Roberts C, Billiodeaux S, Davis DE, Zamanifekri B, Sahraian MA, Alekseeva N, Munjampalli S, Roberts J, Minagar A. Multiple sclerosis and pain.Neurol Res. 2012 Nov;34(9):829-41. doi: 10.1179/1743132812Y.0000000082. Jafarirad S, Siassi F, Harirchian MH, 




129. Jafarirad S1, Siassi F, Harirchian MH, Sahraian MA, Eshraghian MR, Shokri F, Amani R, Bitarafan S, Mozafari S, Saboor-Yaraghi A. The effect of vitamin A supplementation on stimulated T-cell proliferation with myelin oligodendrocyte glycoprotein in patients with multiple sclerosis. J Neurosci Rural Pract. 2012 Sep;3(3):294-8. doi: 10.4103/0976-3147.102609.







130. Naderi F, Javadi SA, Motamedi M, Sahraian MA. The efficacy of primidone in reducing severe cerebellar tremors in patients with multiple sclerosis.Clin Neuropharmacol. 2012 Sep-Oct;35(5):224-6. doi:10.1097/WNF.0b013e31826249bb.




131. Miri S, Rohani M, Sahraian MA, Zamani B, Shahidi GA, Sabet A, Moradi-Lakeh M, Bodaghabadi M. Restless legs syndrome in Iranian patients with multiple sclerosis. Neurol Sci. 2013 Jul;34(7):1105-8. doi: 10.1007/s10072-012







132. Maghzi AH, Sahraian MA, Maghzi H, Shaygannejad V. Multiple sclerosis in Sistan and Baloochestan, South East Iran. Clin Neurol Neurosurg. 2013 Jun;115(6):847-8. doi: 10.1016/j.clineuro.2012.08.014. 







133. Sahraian MA, Radue EW, Eshaghi A, Besliu S, Minagar A. Progressive multifocal leukoencephalopathy: a review of the neuroimaging features and differential diagnosis.Eur J Neurol. 2012 Aug;19(8):1060-9. doi: 10.1111/j.1468-1331.2011.03597.x.










134. Eshaghi A, Riyahi-Alam S, Roostaei T, Haeri G, Aghsaei A, Aidi MR, Pouretemad HR, Zarei M, Farhang S, Saeedi R, Nazeri A, Ganjgahi H, Etesam F, Azimi AR, Benedict RH, Sahraian MA. Validity and reliability of a Persian translation of the Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS).Clin Neuropsychol. 2012;26(6):975-84. doi: 10.1080/13854046.2012.694912.




135. Ghajarzadeh M, Sahraian MA, Fateh R, Daneshmand A. Fatigue, depression and sleep disturbances in Iranian patients with multiple sclerosis.Acta Med Iran. 2012;50(4):244-9.




136. Razeghi E, Sahraian MA, Heidari R, Bagherzadeh M. Association of inflammatory biomarkers with sleep disorders in hemodialysis patients.Acta Neurol Belg. 2012 Mar;112(1):45-9. doi: 10.1007/s13760-012-0003-7.




137. Larijani B, Esfahani EN, Amini P, Nikbin B, Alimoghaddam K, Amiri S, Malekzadeh R, Yazdi NM, Ghodsi M, Dowlati Y, Sahraian MA, Ghavamzadeh A. Stem cell therapy in treatment of different diseases.Acta Med Iran. 2012;50(2):79-96. Review.




138. Sahraian MA, Harandi AA, Kalanie H. New diagnostic criteria for multiple sclerosis in patients with clinically isolated syndromes: Some questions could be raised during clinical practice.Iran J Neurol. 2012;11(3):123-4. 







139. Sahraian MA, Pakdaman H, Harandi AA. Is it time to revise the classification of geographical distribution of multiple sclerosis? Iran J Neurol. 2012;11(2):77-8.




140. Togha M, Sahraian MA, Hosseini SJ, Haddadi A. Brain tuberculoma: Report of a case presented with prolonged nonspecific symptoms and multiple brain tuberculoma.Iran J Neurol. 2012;11(1):34-5. 







141. Metz I, Radue EW, Oterino A, Kümpfel T, Wiendl H, Schippling S, Kuhle J, Sahraian MA, Gray F, Jakl V, Häusler D, Brück W. Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.Acta Neuropathol. 2012 Feb;123(2):235-45. doi: 10.1007/s00401-011-0900-5. 




142. Minagar A, Rabinstein AA, Rezania K, Sih M, Alekseeva N, Petrea RE, Alhajeri A, Nick ST, Gonzalez-Toledo E, Sahraian MA, Kelley RE. Neurologic emergencies: case studies.Neurol Clin. 2012 Feb;30(1):345-56, x. doi: 10.1016/j.ncl.2011.10.002.







143. Mohammadzadeh A, Pourfathollah AA, Sahraian MA, Behmanesh M, Daneshmandi S, Moeinfar Z, Heidari M. Evaluation of apoptosis-related genes: Fas (CD94), FasL (CD178) and TRAIL polymorphisms in Iranian multiple sclerosis patients.J Neurol Sci. 2012 Jan 15;312(1-2):166-9. doi: 10.1016/j.jns.2011.07.037. 




144. Vasheghani-Farahani A, Sahraian MA, Darabi L, Aghsaie A, Minagar A. Incidence of various cardiac arrhythmias and conduction disturbances due to high dose intravenous methylprednisolone in patients with multiple sclerosis.J Neurol Sci. 2011 Oct 15;309(1-2):75-8. doi: 10.1016/j.jns.2011.07.018. 




145. Motamedi M, Sahraian MA, Moshirzadeh S. Perceived impact of epilepsy in teaching hospitals of Tehran University.Iran J Neurol. 2011;10(3-4):43-5.




146. Pozzilli C, Schweikert B, Ecari U, Oentrich W; BetaPlus Study group. Supportive strategies to improve adherence to IFN β-1b in multiple sclerosis--results of the βPlus observational cohort study.J Neurol Sci. 2011 Aug 15;307(1-2):120-6. doi: 10.1016/j.jns.2011.04.026. 



147. Harirchian MH, Tekieh AH, Modabbernia A, Aghamollaii V, Tafakhori A, Ghaffarpour M, Sahraian MA, Naji M, Yazdanbakhsh M. Serum and CSF PDGF-AA and FGF-2 in relapsing-remitting multiple sclerosis: a case-control study. Eur J Neurol. 2011 Jul 19. 



148. Sahraian MA, Maghzi AH, Etemadifar M, Minagar A. Dalfampridine: review of its efficacy in improving gait in patients with multiple sclerosis.J Cent Nerv Syst Dis. 2011 May 16;3:87-93. 




149. Heidari A, Behmanesh M, Sahraian MA, Meshkani R, Darvish H, Najmabadi H, Ohadi M. The human caveolin 1 gene upstream purine complex and neurodegeneration-A common signature. J Neuroimmunol. 2011;236:106-10.



150. Elhami SR, Mohammad K, Sahraian MA, Eftekhar H. A 20-year incidence trend (1989-2008) and point prevalence (march 20, 2009) of multiple sclerosis in tehran, iran: a population-based study. Neuroepidemiology. 2011;36:141-7. 



151. Heidari M, Behmanesh M, Sahraian MA. Variation in SNPs of the IL7Ra gene is associated with multiple sclerosis in the Iranian population. Immunol Invest. 2011;40:279-89.



152. Sahraian MA, Akbari H, Khajavi MR, Najafi A, Khashayar P. The risk factors and the treatment course of cerebral venous thrombosis: an experience of 41 cases.Acta Neurol Belg. 2010 Sep;110(3):230-3.



153. Morteza Mahmoudi M,  Sahraian MA, Shokrgozar MA, Laurent S. Superparamagnetic Iron Oxide Nanoparticles: Promises for Diagnosis and Treatment of Multiple Sclerosis. ACS Chem. Neurosci. 2011; 2:118–140.



154. Sahraian MA, Akbari H, Khajavi MR, Najafi A, Khashayar P. The risk factors and the treatment course of cerebral venous thrombosis: an experience of 41 cases. Acta Neurol Belg. 2010;110:230-3.



155. Sahraian MA, Khorramnia S, Ebrahim MM, Moinfar Z, Lotfi J, Pakdaman H. Multiple sclerosis in Iran: a demographic study of 8,000 patients and changes over time. Eur Neurol. 2010;64:331-6.



156. Sahraian MA, Eshaghi A. Concomitant multiple sclerosis and idiopathic thrombocytopenic purpura. Eur J Neurol. 2010;17:e62-3.



157. Roghani M, Mahboudi F, Saharian MA, Etemadifar M, Esfahani AN, Nahrevanian H, Elahi E. Concentrations of nitric oxide metabolites in the serum of Iranian multiple sclerosis patients. J Neurol Sci. 2010;294:92-4.



158. Togha M, Karvigh SA, Nabavi M, Moghadam NB, Harirchian MH, Sahraian MA, Enzevaei A, Nourian A, Ghanaati H, Firouznia K, Jannati A, Shekiba M. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial. Mult Scler. 2010;16:848-54. 



159. Sahraian MA, Eshaghi A. Role of MRI in diagnosis and treatment of multiple sclerosis. Clin Neurol Neurosurg. 2010 Sep;112:609-15. Review.



160. Sahraian MA, Moinfar Z, Khorramnia S, Ebrahim MM. Relapsing neuromyelitis optica: demographic and clinical features in Iranian patients. Eur J Neurol. 2010;17:794-9. 



161. Minagar A, Alexander JS, Sahraian MA, Zivadinov R. Alemtuzumab and multiple sclerosis: therapeutic application. Expert Opin Biol Ther. 2010;10:421-9. Review.



162. Sahraian MA, Radue EW, Haller S, Kappos L. Black holes in multiple sclerosis: definition, evolution, and clinical correlations. Acta Neurol Scand. 2010;122:1-8. Review



163. Mortaz Hejri S, Mostafazadeh Davani B, Sahraian MA. Carotid endarterectomy for carotid stenosis in patients selected for coronary artery bypass graft surgery. Cochrane Database Syst Rev. 2009 Oct 7: Review.



164. Shokrgozar MA, Sarial S, Amirzargar A, Shokri F, Rezaei N, Arjang Z, Radfar J, Yousefi-Behzadi M, Ali Sahraian M, Lotfi J. IL-2, IFN-gamma, and IL-12 gene polymorphisms and susceptibility to multiple sclerosis. J Clin Immunol. 2009;29:747-51



165. Etemadifar M, Fatehi F, Sahraian MA, Borhanihaghighi A, Ardestani PM, Kaji-Esfahani M, Maghzi AH. Multiple sclerosis and neurofibromatosis type 1: report of seven patients from Iran. Mult Scler. 2009;15:1126-30.



166. Motamedi M, Karvigh SA, Sahraian MA, Azimi AR, Navardi S.  Lamotrigine and twin pregnancy, incidental event or possible correlation? Seizure. 2009;18:580-2



167. Togha M, Sahraian MA, Khorram M, Khashayar P. Warning Signs and Symptoms of Subarachnoid Hemorrhage. South Med J. 2008 Dec 10.



168. Ghabaee M, Omranisikaroudi M, Amrisaroukolaei S, Meysamie A, Sahraian MA, Baya

No items yet!

    No items yet!

    No items yet!